May 06, 2021
New data from a phase 3 study evaluating SGX301 for treatment of cutaneous T-cell lymphoma (CTCL) skin symptoms was recently presented at the American Academy of Dermatology Virtual Meeting Experience (AAD VMX 2021).
May 05, 2021
A study presented at the American Academy of Dermatology Virtual Meeting Experience 2021 exhibited new safety and efficacy data for etrasimod as a potential treatment for atopic dermatitis.
May 04, 2021
According to study data recently presented at AAD VMX 2021, tofacitinib demonstrated positive results when being evaluated as a possible treatment for cutaneous sarcoidosis.
May 03, 2021
Interim analysis of data from the ECZTEND study evaluating the long-term safety, efficacy, and tolerability of tralokinumab for treatment of atopic dermatitis was presented at AAD VMX 2021.
April 30, 2021
A phase 3 trial found different doses of abrocitinib demonstrated efficacy as a treatment for atopic dermatitis.
April 29, 2021
A survey from the American Academy of Dermatology found that younger generations lack skin cancer knowledge.
In recent phase 3 trials, deucravacitinib demonstrated progress toward becoming a potential new treatment in moderate to severe plaque psoriasis.
April 28, 2021
The FDA has set a Prescription Drug User Fee Act (PDUFA) date for bimekizumab (UCB) for the treatment of psoriasis.
